top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • May 4
  • 1 min read

01/05/2026










UCB announced acquisition of IMIDomics’ patient insight business, strengthening capabilities in IMIDs (Ref)


UCB and IMIDomics announced that UCB had acquired the Patients Insights Business of IMIDomics, gaining access to multi-omic datasets for immune mediated inflammatory diseases (IMIDs).


  • The Patient Insight Business enhanced UCB’s ability to identify novel drug targets, discover responder biomarkers, and design molecularly informed patient stratification approaches.



bottom of page